EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of prolonged-release lappaconitine hydrobromide in premature atrial contractions: pilot observational study

Yu. V. Shubik, S. G. Kanorskiy, M. V. Berman, L. V. Polishchuk, A. E. Rivin

Journal of Arrhythmology · 13.06.2026 · 33 (2) · 65-74

DOI: 10.35336/va-1641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Arrhythmology, online erschienen am 13.06.2026. Verfasst von Yu. V. Shubik und 4 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the efficacy and safety of the prolonged-release formulation of lappaconitine hydrobromide at the minimum dose of 25 mg twice daily in patients with premature atrial contractions (PACs) and no structural heart disease.

Methods

This retrospective open-label non-randomized observational study included 52 patients (20 men) aged 31-79 years with symptomatic PACs and/or paroxysmal atrial fibrillation requiring antiarrhythmic therapy. All patients underwent two Holter ECG recordings: before treatment initiation and after 2-3 weeks of therapy with prolonged-release lappaconitine hydrobromide 25 mg twice daily. All quantitative indices of atrial ectopic activity were normalized to 24 hours. Efficacy was assessed by changes in the number of single, paired, and grouped PACs, episodes of paroxysmal focal atrial tachycardia (AT), the ectopic burden index, and the distribution of responders. Safety was assessed by changes in heart rate, P-wave, QRS complex, PQ, QT and QTc intervals duration. Analysis of individual forms of atrial ectopic activity was performed only in patients in whom the corresponding types of arrhythmia were present at baseline and for whom complete data were available to assess their changes during therapy.

Results

Therapy was associated with a statistically significant reduction in all forms of atrial ectopic activity, including single PACs, paired PACs, grouped PACs, and episodes of paroxysmal focal AT (all p 500 PACs per 24 hours). Heart rate decreased moderately; a statistically significant but clinically insignificant increase in the PQ interval was observed. No significant changes were found in P-wave duration, QRS duration, or QT and QTc intervals.

Conclusion

The prolonged-release formulation of lappaconitine hydrobromide at the minimum daily dose of 50 mg provides a statistically significant reduction in atrial ectopic activity in patients without structural heart disease and is characterized by a favorable safety profile when administered twice daily.

Zitieren

APA

Shubik, Y. V., Kanorskiy, S. G., Berman, M. V., Polishchuk, L. V., & Rivin, A. E. (2026). Efficacy and safety of prolonged-release lappaconitine hydrobromide in premature atrial contractions: pilot observational study. Journal of Arrhythmology, 33(2), 65-74. https://doi.org/10.35336/va-1641

Vancouver

Shubik YV, Kanorskiy SG, Berman MV, Polishchuk LV, Rivin AE. Efficacy and safety of prolonged-release lappaconitine hydrobromide in premature atrial contractions: pilot observational study. Journal of Arrhythmology. 2026;33(2):65-74. doi:10.35336/va-1641

BibTeX
@article{Shubik2026,
  author = {Shubik, Yu. V. and Kanorskiy, S. G. and Berman, M. V. and Polishchuk, L. V. and Rivin, A. E.},
  title = {Efficacy and safety of prolonged-release lappaconitine hydrobromide in premature atrial contractions: pilot observational study},
  journal = {Journal of Arrhythmology},
  year = {2026},
  volume = {33},
  number = {2},
  pages = {65--74},
  doi = {10.35336/va-1641}
}
Kostenlos starten →